Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Casdatifan was well tolerated and had durable clinical activity in patients with metastatic clear cell renal cell carcinoma.

Casdatifan Demonstrates Durable Activity in Metastatic Clear Cell Renal Cell Carcinoma

IDE397 is the first MAT2A inhibitor to show clinical activity and safety in patients with MTAP-deletion urothelial cancer and non–small cell lung cancer. 
		 	 	 		


IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC 

The first-in-class CDK8/19 inhibitor RVU120 demonstrated early signs of clinical activity in patients with relapsed/refractory metastatic or advanced solid tumors.

RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors

RMC-9805 was proven safe and active in patients with previously treated, KRAS G12D–mutant pancreatic ductal adenocarcinoma.

RMC-9805 Triggers Tumor Regressions in KRAS G12D–Mutant Pancreatic Cancer

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Biomarker Consortium

Subscribe

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

An indirect comparison did not show significant differences in survival for acalabrutinib vs ibrutinib in relapsed/refractory mantle cell lymphoma.

Indirect Comparison Shows Comparable Efficacy, Improved Safety for Acalabrutinib vs Ibrutinib in R/R Mantle Cell Lymphomal Lymphoma

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Ruxolitinib plus low-dose pegylated interferon alfa-2a is well tolerated and efficacious in patients with newly diagnosed polycythemia vera. 

Ruxolitinib Plus Pegylated Interferon Alfa-2a Is Safe and Effective in in Newly-Diagnosed PV

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Trevor Leong, MBBS, MD, FRANZCR, discusses findings from the TOPGEAR trial assessing perioperative chemoradiotherapy in gastric/GEJ cancer.

Preoperative Radiotherapy Plus Perioperative Chemo Improves pCR Rate but Not Survival in Resectable Gastric/GEJ Cancer

AWS, Deloitte, Microsoft and NVIDIA bring the latest in AI technology, coordination, and compute to the alliance and back with initial funding.

Cancer Centers Launch Cancer AI Alliance to Unlock Discoveries, Transform Care Using Cancer Data and Applied AI

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

Partner

Is your organization missing from this list? Reach out to Leyla Cakici, Strategic Alliance Partnership Coordinator, to learn more about the complimentary strategic partnership program: 

Strategic Alliance Partners

Mayo Clinic

Mayo Clinic | Strategic Alliance Partners

Latest from Mayo Clinic

Latest Conference Coverage